Pay in 4 interest-free payments of $5.92 Learn more
Ships within 48 hours · Estimated delivery Aug 14 - Aug 19
This is a preview of subscription content, access via your institution Access options Access Nature and 54 other Nature Portfolio journals Get Nature+, our best-value online-access subscription $32.99 / 30 days cancel any time Subscribe to this journal Receive 12 print issues and online access $189.00 per year only $15.75 per issue Buy this article Purchase on SpringerLink Instant access to the full article PDF
2) In addition to testing various doses of cagrilintide, the peptide was also tested in combination with semaglutide, a GLP-1 receptor agonist, in order to assess the impact treatment has on HbA1c levels in participants diagnosed with type 2 diabetes mellitus
Therefore, this drug class offers benefits for obesity in patients with type 2 diabetes, a common comorbidity
Slide it in with a quick, confident motion
